”“Given that a majority of the baseline pharma challenges have been solved, it is the current need for more complex treatments that is driving the need to invest significantly more into R&D,” according to the experts. “As this impact is seen in the length of research, cost of development and lack of deliverable drugs to bring to the market, Big Pharma will be forced to reevaluate their business model, figuring out how they can invest in startups, buy pipelines, bring incubator spaces into the market, create flexible labs space, and much more. As these new industry realities transform how new products are discovered, manufactured and brought to market – it will drive real estate and facilities decisions.
“Without productive, efficient R&D processes that deliver strong revenues to drive reinvestment into continuing innovation, the business model falls apart,” says Roger Humphrey, executive managing director and leader of JLL’s Life Sciences group. “In 2019, Big Pharma will focus on solving the R&D conundrum through investing in startups, buying pipelines, bringing incubator spaces into the market, creating flexible lab spaces, embarking on joint ventures and more.”Andrew HumphreysPharmaLive